Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCENT: ABBV-RGX-314 in wet AMD
NCT05407636Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2022
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 10
01
Overview
Phase 3, randomised, single-blind trial of surabgene lomparvovec in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Best Corrected Visual Acuity at 54 weeks and Adverse Events at 50 weeks. Started Jan 2022; status: active, not recruiting.
02
Drugs
surabgene lomparvovec
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT05407636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407636.